News

electroCore Announces Issuance of Two New U.S. Patents

ROCKAWAY, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that…

2 years ago

Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

Continued Positive Safety Data for OCU400 Established High Dose as the Maximum Tolerable Dose in Current OCU400 Clinical Trial MALVERN,…

2 years ago

Petalfast Partners with Eagle Eyes Transport for Secure Cannabis Distribution in Massachusetts

Massachusetts supply chain specialist to provide Petalfast’s portfolio of brands statewide compliant transportation and safeguarded distribution servicesIRVINE, Calif., Dec. 07,…

2 years ago

BetterLife Announces Closing of Private Placement

VANCOUVER, British Columbia, Dec. 07, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB :…

2 years ago

Stryker declares a $0.75 per share quarterly dividend

Kalamazoo, Michigan, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly…

2 years ago

RIGImmune Announces New Funding to Advance Development of RNA Virus Treatments

Program-Related Investment and Grant from the Bill & Melinda Gates Foundation to advance RIGImmune’s RNA therapeutics platform for influenza and…

2 years ago

PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies

DMPK Transcript Levels Figure 1. No significant changes in mean DMPK transcript levels were observed in DM1 patient cells or…

2 years ago

Cerevance to Present at the RBC Capital Markets Virtual Healthcare Private Company Conference

BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous…

2 years ago

BioVie Issues Letter to Shareholders

Parkinson’s disease (PD) patients treated with NE3107 for 28 days experienced a clinically meaningful increase in motor control.Additional data presented…

2 years ago

IntelGenx Announces Collaboration with UPEI to Evaluate Acceptance and Preference of VetaFilm™ Platform in Dogs and Cats

SAINT LAURENT, Quebec, Dec. 07, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical…

2 years ago